Sputtr.com | Alternative Search Engine


5.8 Cerebrovascular Accident

® HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TARCEVA safely and effectively. See full prescribing information for TARCEVA.

Tarceva: advancing the standard of care in pancreatic cancer

Tarceva in combination with gemcitabine is indicated for first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Tarceva rash management guide

®Please see important safety information on pages 14-15 and enclosed full prescribing information. Tarceva rash management guide Safety and effectiveness have not been studied in pediatric patients.

Oral Oncology Agents - Tarceva (erlotinib) Prior ...

Proprietary Information of Blue Cross and Blue Shield of Alabama Page 1 of 3 Oral Oncology Agents - Tarceva (erlotinib) Prior Authorization Coverage Criteria POLICY #: 4026 CATEGORY: Medicare Part D This prior authorization program applies to new prescription starts only.


NEWS RELEASE Genentech Contacts: Media: Charlotte Arnold (650) 467-6800 Advocacy: Jen Mills (415) 971-2409 Investor: Karl Mahler 011 41 61 687 8503 Thomas Kudsk Larsen ...

Tarceva® Covered Medication

Tarceva July 2010 Tarceva ® Covered Medication Erlotinib (Tarceva ®) What it does and how it is used  Lung cancer is the leading cause of cancer death in men and women in the United States.

It is not known whether erlotinib passes into breast milk. It ...

TARCEVA ® Film-Coated Tablets pronounced "tar-see-va" contains the active ingredient erlotinib Consumer Medicine Information What is in this leaflet This leaflet answers some common


7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7<sector fax> E-mail info@ema.europa. eu Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2011.


IMPORTANT: PLEASE READ Page 3 of 5 PART III: CONSUMER INFORMATION PrTARCEVA®TARCEVATM (erlotinib hydrochloride tablets) This leaflet is part III of a three-part "Product Monograph"

Tarceva® (erlotinib) Tablets NDA 21-743, S003 Supplemental ...

Tarceva ® (erlotinib) Tablets, NDA 21-743, S003: Supplemental NDA Briefing Document - 13 September 2005 ODAC Meeting Page 3 09 AUG 2005 5.2.5 Laboratory Abnormalities..... 50 5.3 Safety Conclusions ...